Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review

Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by e...

Full description

Bibliographic Details

Published in:	Frontiers in Endocrinology
Main Authors:	Xiangyun You, Shan Huang, Xin’an Wang, Cheng Yi, Niandong Gong, Junfeng Yu, Chengdang Xu, Zhendong Xiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Subjects:	bipolar androgen therapy testosterone castration-resistant prostate cancer abiraterone enzalutamide
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.1125838/full